What does FDA approval of Merck’s first oral PCSK9 therapy mean?

The FDA has cleared Merck’s oral PCSK9 drug, marking the first pill form in a class previously limited to injectables. The decision could reshape cholesterol treatment by improving adherence and convenience, potentially expanding use into broader prevention markets and pressuring injectable competitors on price and market share.